Internal Medicine, Nephrology · Winter Park, FL
NPI
1821081985
Since 2005
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
4100 Metric Dr, Suite 200
Winter Park, FL, 32792
Phone (407) 681-8720
Groups this clinician bills Medicare through
Medicare paid, 2024
$644K
15,574 services
Medicare patients, 2024
1,377
Average age 78
Drug cost, 2024
$569K
3,022 prescriptions
Company payments, 2025
$2,858
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark A Lagatta was code 99232 (hospital e&m - subsequent), 4,006 times for 693 patients. In total Mark A Lagatta billed 15,574 services in 58 codes, and Medicare paid $644K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-12-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 4,006 | 693 | $61.11 | $245K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 1,880 | 19 | $5.06 | $9,510 |
| 81003 Clinical Chemistry | Office | 1,007 | 600 | $2.18 | $2,199 |
| 99214 Office E&M - Established | Office | 884 | 503 | $70.36 | $62K |
| 99233 Hospital E&M - Subsequent | Facility | 796 | 329 | $91.97 | $73K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 702 | 443 | $12.63 | $8,865 |
| 99222 Hospital E&M - Initial | Facility | 522 | 445 | $100.42 | $52K |
| 90960 ESRD Related Services (not dialysis) | Office | 319 | 50 | $268.88 | $86K |
| 36415 Venipuncture Blood Collection | Office | 252 | 148 | $8.58 | $2,163 |
| 90935 Hemodialysis | Facility | 241 | 90 | $54.70 | $13K |
| 99223 Hospital E&M - Initial | Facility | 222 | 186 | $132.36 | $29K |
| 99213 Office E&M - Established | Office | 165 | 158 | $48.66 | $8,028 |
| 80053 Clinical Chemistry | Office | 130 | 91 | $10.35 | $1,346 |
| 99204 Office E&M - New | Office | 118 | 118 | $120.24 | $14K |
| 85018 Blood Count | Office | 105 | 23 | $2.32 | $244 |
By year: 2022 $582K for 30,416 services; 2023 $623K for 28,409 services; 2024 $644K for 15,574 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 1,007 | 600 | $2.18 | $2,199 |
| 36415 Venipuncture Blood Collection | 252 | 148 | $8.58 | $2,163 |
| 80053 Clinical Chemistry | 130 | 91 | $10.35 | $1,346 |
| 85018 Blood Count | 105 | 23 | $2.32 | $244 |
| 82570 Clinical Chemistry | 87 | 66 | $5.08 | $442 |
| 85025 Blood Count | 71 | 48 | $7.61 | $540 |
| 82043 Clinical Chemistry | 66 | 51 | $5.66 | $374 |
| 84156 Clinical Chemistry | 46 | 32 | $3.60 | $166 |
| 80069 Clinical Chemistry | 45 | 41 | $8.51 | $383 |
| 84100 Clinical Chemistry | 39 | 26 | $4.65 | $181 |
Medicare prescription drug claims, 2024
In 2024, the drug Mark A Lagatta prescribed most often to Medicare patients was Losartan Potassium, with 365 prescriptions and refills. In total Mark A Lagatta wrote 3,022 Medicare prescriptions that cost $569K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Losartan Potassium Generic | 365 | 1,002 | 136 | $3,802 |
| Bumetanide Generic | 217 | 458 | 70 | $4,686 |
| Nifedipine Er Nifedipine | 195 | 482 | 59 | $6,057 |
| Olmesartan Medoxomil Generic | 184 | 428 | 60 | $2,628 |
| Allopurinol Generic | 133 | 362 | 42 | $1,191 |
| Spironolactone Generic | 119 | 264 | 42 | $1,073 |
| Carvedilol Generic | 113 | 265 | 34 | $832 |
| Potassium Chloride Generic | 101 | 194 | 42 | $4,294 |
| Furosemide Generic | 95 | 237 | 41 | $515 |
| Amlodipine Besylate Generic | 95 | 239 | 44 | $595 |
| Chlorthalidone Generic | 92 | 217 | 33 | $1,322 |
| Lisinopril Generic | 73 | 212 | 30 | $681 |
| Veltassa Patiromer Calcium Sorbitex | 65 | 76 | 19 | $90K |
| Farxiga Dapagliflozin Propanediol | 64 | 136 | 21 | $73K |
| Tamsulosin Hcl Generic | 64 | 142 | 19 | $795 |
Brand drugs: 310 claims; generic drugs: 2,712 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark A Lagatta $2,858 ($2,858 in general payments such as food, travel and fees) from 26 companies. The largest payer was Travere Therapeutics, Inc. with $1,130.
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. TVTX | 68 | $1,130 |
| Amgen Inc. AMGN | 9 | $255 |
| Mallinckrodt Hospital Products Inc. | 8 | $200 |
| Calliditas Therapeutics US Inc. | 5 | $120 |
| Xeris Pharmaceuticals, Inc. | 5 | $105 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 4 | $104 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $84.3 |
| Ardelyx, Inc. ARDX | 3 | $81.45 |
| Vifor Pharma, Inc. | 3 | $76.27 |
| Aurinia Pharma U.S., Inc. AUPH | 3 | $67.08 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.